Concepedia

Thomas Harrity

TH

Statistics

Publications

34

Citations

2.1K

H-Index

27

Active since

1974

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

Bristol-Myers Squibb (Sweden)

Institute for Medical Research

Protein Express (United States)

Thomas Harrity is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, medicinal chemistry, and enzyme inhibition.

Publications per year

1974–2017

34

Publications

34

An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits

John R. Wetterau, Richard E. Gregg, Thomas Harrity et al. · Science · 1998 · 269 citations

, , +17

The Ability of Statins to Inhibit Bone Resorption Is Directly Related to Their Inhibitory Effect on HMG-CoA Reductase Activity

Ada Staal, Julie C. Frith, M. H. French et al. · Journal of Bone and Mineral Research · 2003 · 174 citations

, , +17

Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP)

Richard Sulsky, David R. Magnin, Yanting Huang et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 151 citations · Full text

, , +13

An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells.

H Jamil, David A. Gordon, David C. Eustice et al. · Proceedings of the National Academy of Sciences · 1996 · 149 citations

, , +17

Design and Synthesis of <i>N</i>-[(4-Methoxyphenoxy)carbonyl]-<i>N</i>-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering Activities

Pratik Devasthale, Sean Chen, Yoon Jeon et al. · Journal of Medicinal Chemistry · 2004 · 108 citations · Full text

, , +13

1–5 of 34